Coherus offloads Humira biosimilar Yusimry for $40m
Coherus Biosciences has divested Yusimry (adalimumab-aqvh), a biosimilar to AbbVie’s rheumatoid arthritis therapy Humira, to Hong Kong King-Friend Industrial (HKF)…
Coherus Biosciences has divested Yusimry (adalimumab-aqvh), a biosimilar to AbbVie’s rheumatoid arthritis therapy Humira, to Hong Kong King-Friend Industrial (HKF)…
Scientists from the universities of Birmingham and Sheffield have partnered with NLC Health Ventures for the launch of Midland Pharmaceuticals…
The European Commission (EC) has granted marketing authorisation for Sandoz’s biosimilars Wyost (denosumab) and Jubbonti (denosumab) for bone-related ailments. Wyost…
Alvotech has entered a collaboration with Dr Reddy's Laboratories for the commercialisation of AVT03 in the US, Europe and the…
The US Food and Drug Administration (FDA) has approved an alternative formulation for Neurocrine Biosciences’ Huntington’s disease therapy, Ingrezza (valbenazine).…
France-based Juvisé Pharmaceuticals has acquired global marketing rights, excluding the US and Canada, for Johnson & Johnson (J&J)’s multiple sclerosis…
Sun Pharmaceutical Industries has announced a recall of 55,000 bottles of Febuxostat, a medication used to treat gout, from the…
The US Food and Drug Administration (FDA) has approved Sandoz’s Wyost (denosumab-bbdz) and Jubbonti (denosumab-bbdz), marking the introduction of the…
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for a new formulation of Amgen’s XGEVA…
Biogen has received a positive opinion from the European Medicines Agency (EMA) committee recommending approval for Qalsody (tofersen) to treat…